Explore this week’s public health highlights, including new developments, pipeline updates, and progress from biopharma leaders
In Today’s Newsletter
Dive deeper
🍼 GLP-1 use and pregnancy risks [1] [US • 24 Nov 2025]
Context: Retrospective study of about 450 singleton pregnancies at Mass General Brigham.
Key point: Prior GLP-1 receptor agonist use was associated with higher rates of adverse outcomes (endpoint details per source) compared with BMI-matched nonusers.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
💉 Tezepelumab as a steroid-sparing option [2] [26 Nov 2025]
Context: Year-long study in 298 adults with severe asthma dependent on daily oral steroids.
Key point: Monthly tezepelumab enabled many patients to eliminate or reduce chronic oral steroids under supervised tapering.
Implication: May influence prescriber choice and payer reviews pending full data.
🩸 Galleri blood test performance concerns [3] [UK • 26 Nov 2025]
https://www.sciencealert.com/exciting-new-cancer-blood-test-results-hide-a-concerning-problem
Context: NHS-linked Pathfinder 2 study in over 23,000 older adults.
Key point: High specificity but low sensitivity, with population-level false positives and missed cancers highlighted by experts.
Implication: Observational findings could inform practice; interpretation depends on study design and confounding control.
🍽️ Most people meet protein needs without tracking [4] [24 Nov 2025]
Context: Expert commentary on protein intake in high-income countries.
Key point: Protein deficiency is rare; excessive focus on protein may overshadow other nutrient gaps.
Implication: Could inform practice and payer discussions; interpretation depends on context.
🦵 Buttock muscle shape and metabolic risk [5] [UK • 25 Nov 2025]
Context: MRI-based shape mapping in over 61,000 UK Biobank participants.
Key point: Gluteus maximus shape correlated with activity, frailty, sitting time, and type 2 diabetes in sex-specific patterns.
Implication: Observational findings could inform practice; interpretation depends on study design and confounding control.
🧬 mRNA peptibody therapy for resistant pneumonia [6] [27 Nov 2025]
https://www.drugtargetreview.com/news/190978/new-mrna-therapy-targets-drug-resistant-pneumonia/
Context: Preclinical models in mice and human lung tissue.
Key point: mRNA-encoded peptibodies reduced lung bacterial burden and inflammation versus standard treatments.
Implication: Signals pipeline investment and modality expansion.
🧫 Environmental chemicals harming gut bacteria [7] [26 Nov 2025]
https://medicalxpress.com/news/2025-11-pesticides-common-chemical-pollutants-toxic.html
Context: Screen of 1,076 chemicals against 22 gut bacterial species.
Key point: 168 chemicals inhibited beneficial bacteria, with some resistance mechanisms overlapping with antibiotic resistance.
Implication: Could inform practice and payer discussions; interpretation depends on study design.
🧪 MIT’s BoltzGen generative AI for binder design [8] [US • 25 Nov 2025]
Context: Validation across 26 protein targets and eight independent wet labs.
Key point: Open-source BoltzGen produced nanomolar binders on many difficult targets and unifies structure prediction with design.
Implication: Signals pipeline investment and modality expansion.
⚖️ Cardiometabolic reversal after tirzepatide withdrawal [9] [24 Nov 2025]
https://www.medpagetoday.com/endocrinology/obesity/118686
Context: Post-hoc SURMOUNT-4 analysis in 308 adults after 36 weeks of tirzepatide.
Key point: Weight regain after stopping correlated with worsening blood pressure, glycemic markers, and waist circumference.
Implication: May influence prescriber choice and payer reviews pending full data.
🔬 RA immune changes years before symptoms [10] [26 Nov 2025]
https://www.sciencedaily.com/releases/2025/11/251126095037.htm
Context: Longitudinal follow-up of individuals with RA-associated autoantibodies for up to seven years.
Key point: Systemic immune dysregulation detected well before clinical RA, including altered B cells, T cells, and monocytes.
Implication: Could inform practice and payer discussions; interpretation depends on study design.
Why it matters
- Preclinical disease signatures (e.g., RA) may enable earlier risk stratification.
- Drug-withdrawal analyses refine expectations for chronic obesity treatments.
- High-specificity but low-sensitivity screening tests require careful population-level interpretation.
- Environmental and lifestyle exposures continue to show broad metabolic and microbiome effects.
- Open-source AI design tools may accelerate global therapeutic development capacity.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
View the full Public Health archive on our research hub page.
FAQ
What did the Mass General Brigham study suggest about GLP-1 RA exposure and pregnancy? [1]
It found higher rates of several adverse pregnancy-related outcomes among prior GLP-1 users compared with BMI-matched nonusers (endpoint not specified), though confounding and incomplete BMI data limit interpretation.
How does tezepelumab reduce reliance on oral steroids in severe asthma? [2]
A year-long study showed many patients could taper or discontinue chronic oral steroids under supervision while receiving monthly tezepelumab, supporting its steroid-sparing potential.
Why are experts cautious about the Galleri multi-cancer blood test? [3]
Despite high specificity, its low sensitivity means many cancers are missed, and population-scale use could generate substantial false positives, with no evidence yet of reduced mortality.
What metabolic pattern was linked to tirzepatide discontinuation? [9]
In SURMOUNT-4, weight regain after stopping tirzepatide was associated with worsening cardiometabolic markers, suggesting benefits may not persist without ongoing therapy.
What early immune changes were detected in people at risk of RA? [10]
Researchers observed systemic inflammation, pro-inflammatory B cell and T helper subsets, and macrophage-like monocytes years before symptoms, indicating early disease activity.
Entities / Keywords
GLP-1 receptor agonists, Ozempic, Wegovy, Zepbound, tezepelumab, Galleri, protein intake, type 2 diabetes, mRNA therapy, multidrug-resistant pneumonia, environmental chemicals, gut microbiome, BoltzGen, tirzepatide, SURMOUNT-4, rheumatoid arthritis.
References
- https://www.livescience.com/health/fertility-pregnancy-birth/study-links-glp-1-use-to-some-pregnancy-risks-but-the-study-has-key-caveats
- https://www.newscientist.com/article/2506011-monthly-injection-could-replace-daily-steroid-pills-for-severe-asthma/
- https://www.sciencealert.com/exciting-new-cancer-blood-test-results-hide-a-concerning-problem
- https://www.cnet.com/health/nutrition/expert-explains-why-stop-worrying-about-how-much-protein-youre-eating/
- https://www.upi.com/Health_News/2025/11/25/buttocks-shape-frailty-diabetes-risk-aging-study/2541764081630/
- https://www.drugtargetreview.com/news/190978/new-mrna-therapy-targets-drug-resistant-pneumonia/
- https://medicalxpress.com/news/2025-11-pesticides-common-chemical-pollutants-toxic.html
- https://news.mit.edu/2025/mit-scientists-debut-generative-ai-model-that-could-create-molecules-addressing-hard-to-treat-diseases-1125
- https://www.medpagetoday.com/endocrinology/obesity/118686
- https://www.sciencedaily.com/releases/2025/11/251126095037.htm